NEWTON, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimerโs disease, announced today that management will participate in a fireside chat at the Stifel Healthcare Conference on Tuesday, Nov. 11, 2025, at 4:40 p.m. ET.
The live webcasts may be accessed under the Investors tab onย www.acumenpharm.comย and will be archived for 90 days.
About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AฮฒOs) for the treatment of Alzheimerโs disease (AD). Acumenโs scientific founders pioneered research on AฮฒOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimerโs disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AฮฒOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimerโs disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. Acumen is also investigating a subcutaneous formulation of sabirnetug using Halozymeโs proprietary ENHANZEยฎย drug delivery technology. Acumen is also collaborating with JCR Pharmaceuticals to develop an Enhanced Brain Delivery (EBDโข) therapy for Alzheimerโs disease utilizing a transferrin-receptor-targeting blood-brain barrier-penetrating technology. The company is headquartered in Newton, Mass. For more information, visitย www.acumenpharm.com.โฏโฏโฏ
Investors:
Alex Braun
abraun@acumenpharm.com
Media:ย
AcumenPR@westwicke.comย
